Purpose: Line Operations Safety Audit (LOSA) has reduced errors by detecting and managing threats and errors of flight deck crew in the cockpit during normal flight operations. Airlines can understand the countermeasures and competencies of the crew and the success of error management. This paper introduces the advantages of LOSA and how LOSA data collection can be enhanced for the safety of flight operations. Methods: It analyzed the components of data collection tool in the International Civil Aviation Organization Doc 9803, LOSA manual to find out the deficiencies for enhancement. Results: Five suggestions are proposed in this study, codes for positive activities and the development of a form, the development of proactive strategies that predict threats in advance and manage the threats and management of errors, to describe the coding and narrative for successful briefings that manage threats and errors and codes for positive culture are required for successful LOSA data collection flight operations. Conclusion Safety Management System, Threat and Error Management, LOSA, and other conventional safety tools manage safety based on risk or failure, so if we change the paradigm, we can train more safety-resilient pilots. The tragic outcomes such as accidents or incidents have the problem of low occurrence probability, but if we supplement and utilize LOSA data of normal flights, we can prevent accidents or nearaccidents in advance.

Background/Aims: Fexuprazan, a novel potassium-competitive acid blocker, was developed for treating acid-related disorders. Pharmacokinetic and pharmacodynamic properties of fexuprazan, unlike those of proton pump inhibitors, are independent of food effect. This study aims to evaluate differences in efficacy and safety of fexuprazan in patients with erosive esophagitis (EE) according to the timing of dosing. Methods: In this multicenter, open-label noninferiority study, patients who had typical reflux symptoms with endoscopically confirmed EE were randomized 1:1 to receive fexuprazan 40 mg daily 30 minutes before or after meal. Treatment was completed after 2 weeks or 4 weeks when healing was endoscopically confirmed. The primary endpoint was the proportion of patients with healed EE confirmed by endoscopy up to week 4. Safety endpoints included treatment-emergent adverse events (TEAEs). Results: In the prior-to-meal group (n = 89) and after-meal group (n = 86), 4-week EE healing rates were 98.77% and 100.00% (difference, 0.01%; 95% CI, –0.01% to 0.04%) and 2-week EE healing rates were 95.77% and 97.14% (difference, 0.01%; 95% CI, –0.05% to 0.07%), respectively. TEAEs were 9.78% and 8.70% in the prior-to-meal group and the after-meal group, respectively. Conclusions Non-inferiority analysis revealed that taking fexuprazan after meal was non-inferior to taking fexuprazan before meals in patients with EE. The frequency of adverse events was similar between the 2 study groups. The drug is safe and effective for healing EE regardless of the timing of dosing.

We report a case of complete remission in anaplastic oligodendroglioma following adoptive cell therapy (ACT) with autologous Wilms tumor 1 (WT-1)-specific CD8+ T cells. A 40-year-old woman referred to our hospital for adjuvant chemotherapy after recurrent anaplastic oligodendroglioma initially presented with a left frontal tumor, diagnosed through seizure onset, and subtotal resection confirmed oligodendroglioma (WHO grade 2). Radiation therapy treated the residual tumor, achieving partial remission until recurrence 2.5 years later when malignant transformation to anaplastic oligodendroglioma (WHO grade 3) occurred following a second craniotomy. After three cycles of procarbazine, lomustine, and vincristine chemotherapy, the residual tumor stabilized for 3 years. However, follow-up MRI identified a new enhancing lesion, prompting a third craniotomy. Recurrent anaplastic oligodendroglioma was confirmed, and adjuvant proton beam therapy and temozolomide chemotherapy were initiated. Two years later, another enhancing lesion appeared on the adjacent medial frontal lobe. Following multidisciplinary review, we introduced WT-1-specific ACT. Although transient swelling was observed 1 month post-therapy, the tumor demonstrated a response within 3–9 months. Continued regression led to complete remission—confirmed via MRI at the 15-month follow-up and sustained for 4.7 years. The patient’s peripheral blood monocyte profiles and immune-associated cytokine analysis indicated T-cell activation following WT-1 sensitization.

Purpose: Line Operations Safety Audit (LOSA) has reduced errors by detecting and managing threats and errors of flight deck crew in the cockpit during normal flight operations. Airlines can understand the countermeasures and competencies of the crew and the success of error management. This paper introduces the advantages of LOSA and how LOSA data collection can be enhanced for the safety of flight operations. Methods: It analyzed the components of data collection tool in the International Civil Aviation Organization Doc 9803, LOSA manual to find out the deficiencies for enhancement. Results: Five suggestions are proposed in this study, codes for positive activities and the development of a form, the development of proactive strategies that predict threats in advance and manage the threats and management of errors, to describe the coding and narrative for successful briefings that manage threats and errors and codes for positive culture are required for successful LOSA data collection flight operations. Conclusion Safety Management System, Threat and Error Management, LOSA, and other conventional safety tools manage safety based on risk or failure, so if we change the paradigm, we can train more safety-resilient pilots. The tragic outcomes such as accidents or incidents have the problem of low occurrence probability, but if we supplement and utilize LOSA data of normal flights, we can prevent accidents or nearaccidents in advance.

Purpose: Line Operations Safety Audit (LOSA) has reduced errors by detecting and managing threats and errors of flight deck crew in the cockpit during normal flight operations. Airlines can understand the countermeasures and competencies of the crew and the success of error management. This paper introduces the advantages of LOSA and how LOSA data collection can be enhanced for the safety of flight operations. Methods: It analyzed the components of data collection tool in the International Civil Aviation Organization Doc 9803, LOSA manual to find out the deficiencies for enhancement. Results: Five suggestions are proposed in this study, codes for positive activities and the development of a form, the development of proactive strategies that predict threats in advance and manage the threats and management of errors, to describe the coding and narrative for successful briefings that manage threats and errors and codes for positive culture are required for successful LOSA data collection flight operations. Conclusion Safety Management System, Threat and Error Management, LOSA, and other conventional safety tools manage safety based on risk or failure, so if we change the paradigm, we can train more safety-resilient pilots. The tragic outcomes such as accidents or incidents have the problem of low occurrence probability, but if we supplement and utilize LOSA data of normal flights, we can prevent accidents or nearaccidents in advance.

Neuronal intranuclear inclusion disease (NIID) is a rare neurodegenerative disorder characterized by the presence of eosinophilic nuclear inclusions in neurons and somatic cells. It clinically manifests as cognitive decline, seizures, and autonomic dysfunction. A 44-year-old man presented with a transient visual field defect and hemiparesis. Based on characteristic imaging findings and pathological findings, NIID was suspected and diagnosed through genetic testing. This case emphasizes the importance of comprehensive clinical phenotype analysis and accurate genetic diagnosis.

We report a case of complete remission in anaplastic oligodendroglioma following adoptive cell therapy (ACT) with autologous Wilms tumor 1 (WT-1)-specific CD8+ T cells. A 40-year-old woman referred to our hospital for adjuvant chemotherapy after recurrent anaplastic oligodendroglioma initially presented with a left frontal tumor, diagnosed through seizure onset, and subtotal resection confirmed oligodendroglioma (WHO grade 2). Radiation therapy treated the residual tumor, achieving partial remission until recurrence 2.5 years later when malignant transformation to anaplastic oligodendroglioma (WHO grade 3) occurred following a second craniotomy. After three cycles of procarbazine, lomustine, and vincristine chemotherapy, the residual tumor stabilized for 3 years. However, follow-up MRI identified a new enhancing lesion, prompting a third craniotomy. Recurrent anaplastic oligodendroglioma was confirmed, and adjuvant proton beam therapy and temozolomide chemotherapy were initiated. Two years later, another enhancing lesion appeared on the adjacent medial frontal lobe. Following multidisciplinary review, we introduced WT-1-specific ACT. Although transient swelling was observed 1 month post-therapy, the tumor demonstrated a response within 3–9 months. Continued regression led to complete remission—confirmed via MRI at the 15-month follow-up and sustained for 4.7 years. The patient’s peripheral blood monocyte profiles and immune-associated cytokine analysis indicated T-cell activation following WT-1 sensitization.

Background/Aims: Fexuprazan, a novel potassium-competitive acid blocker, was developed for treating acid-related disorders. Pharmacokinetic and pharmacodynamic properties of fexuprazan, unlike those of proton pump inhibitors, are independent of food effect. This study aims to evaluate differences in efficacy and safety of fexuprazan in patients with erosive esophagitis (EE) according to the timing of dosing. Methods: In this multicenter, open-label noninferiority study, patients who had typical reflux symptoms with endoscopically confirmed EE were randomized 1:1 to receive fexuprazan 40 mg daily 30 minutes before or after meal. Treatment was completed after 2 weeks or 4 weeks when healing was endoscopically confirmed. The primary endpoint was the proportion of patients with healed EE confirmed by endoscopy up to week 4. Safety endpoints included treatment-emergent adverse events (TEAEs). Results: In the prior-to-meal group (n = 89) and after-meal group (n = 86), 4-week EE healing rates were 98.77% and 100.00% (difference, 0.01%; 95% CI, –0.01% to 0.04%) and 2-week EE healing rates were 95.77% and 97.14% (difference, 0.01%; 95% CI, –0.05% to 0.07%), respectively. TEAEs were 9.78% and 8.70% in the prior-to-meal group and the after-meal group, respectively. Conclusions Non-inferiority analysis revealed that taking fexuprazan after meal was non-inferior to taking fexuprazan before meals in patients with EE. The frequency of adverse events was similar between the 2 study groups. The drug is safe and effective for healing EE regardless of the timing of dosing.

Neuronal intranuclear inclusion disease (NIID) is a rare neurodegenerative disorder characterized by the presence of eosinophilic nuclear inclusions in neurons and somatic cells. It clinically manifests as cognitive decline, seizures, and autonomic dysfunction. A 44-year-old man presented with a transient visual field defect and hemiparesis. Based on characteristic imaging findings and pathological findings, NIID was suspected and diagnosed through genetic testing. This case emphasizes the importance of comprehensive clinical phenotype analysis and accurate genetic diagnosis.

Purpose: Line Operations Safety Audit (LOSA) has reduced errors by detecting and managing threats and errors of flight deck crew in the cockpit during normal flight operations. Airlines can understand the countermeasures and competencies of the crew and the success of error management. This paper introduces the advantages of LOSA and how LOSA data collection can be enhanced for the safety of flight operations. Methods: It analyzed the components of data collection tool in the International Civil Aviation Organization Doc 9803, LOSA manual to find out the deficiencies for enhancement. Results: Five suggestions are proposed in this study, codes for positive activities and the development of a form, the development of proactive strategies that predict threats in advance and manage the threats and management of errors, to describe the coding and narrative for successful briefings that manage threats and errors and codes for positive culture are required for successful LOSA data collection flight operations. Conclusion Safety Management System, Threat and Error Management, LOSA, and other conventional safety tools manage safety based on risk or failure, so if we change the paradigm, we can train more safety-resilient pilots. The tragic outcomes such as accidents or incidents have the problem of low occurrence probability, but if we supplement and utilize LOSA data of normal flights, we can prevent accidents or nearaccidents in advance.